JP2011524745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524745A5 JP2011524745A5 JP2011512892A JP2011512892A JP2011524745A5 JP 2011524745 A5 JP2011524745 A5 JP 2011524745A5 JP 2011512892 A JP2011512892 A JP 2011512892A JP 2011512892 A JP2011512892 A JP 2011512892A JP 2011524745 A5 JP2011524745 A5 JP 2011524745A5
- Authority
- JP
- Japan
- Prior art keywords
- building blocks
- oligonucleotide molecule
- hrp
- nucleotide
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 6
- 102100039389 Hepatoma-derived growth factor-related protein 3 Human genes 0.000 claims 5
- 101710161031 Hepatoma-derived growth factor-related protein 3 Proteins 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 claims 2
- 102000009353 PWWP domains Human genes 0.000 claims 2
- 108050000223 PWWP domains Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 102100031017 Hepatoma-derived growth factor-like protein 1 Human genes 0.000 claims 1
- 102100031001 Hepatoma-derived growth factor-related protein 2 Human genes 0.000 claims 1
- 101710161030 Hepatoma-derived growth factor-related protein 2 Proteins 0.000 claims 1
- 101001083786 Homo sapiens Hepatoma-derived growth factor-like protein 1 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- -1 antisense molecule Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 238000007877 drug screening Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 108010093345 lens epithelium-derived growth factor Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6057108P | 2008-06-11 | 2008-06-11 | |
| US61/060,571 | 2008-06-11 | ||
| PCT/EP2009/004186 WO2009149921A2 (en) | 2008-06-11 | 2009-06-10 | Inhibition of hrp-3 using modified oligonucleotides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524745A JP2011524745A (ja) | 2011-09-08 |
| JP2011524745A5 true JP2011524745A5 (enExample) | 2012-07-12 |
| JP5559159B2 JP5559159B2 (ja) | 2014-07-23 |
Family
ID=41130624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512892A Expired - Fee Related JP5559159B2 (ja) | 2008-06-11 | 2009-06-10 | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8710021B2 (enExample) |
| EP (1) | EP2304031A2 (enExample) |
| JP (1) | JP5559159B2 (enExample) |
| AU (1) | AU2009256906A1 (enExample) |
| CA (1) | CA2727285A1 (enExample) |
| WO (1) | WO2009149921A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130371A1 (en) * | 2010-04-13 | 2011-10-20 | Life Technologies Corporation | Compositions and methods for inhibition of nucleic acids function |
| KR101701235B1 (ko) * | 2013-09-30 | 2017-02-03 | 한국원자력의학원 | Ｈｒｐ-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물 |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| CN116059236A (zh) | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| KR20260009385A (ko) | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994001550A1 (en) * | 1992-07-02 | 1994-01-20 | Hybridon, Inc. | Self-stabilized oligonucleotides as therapeutic agents |
| US6699843B2 (en) * | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| US6893844B1 (en) * | 1998-09-22 | 2005-05-17 | Long Yu | DNA encoding a new human hepatoma derived growth factor and producing method thereof |
| US20030198953A1 (en) | 2000-03-30 | 2003-10-23 | Spytek Kimberly A. | Novel proteins and nucleic acids encoding same |
| AU2003256857A1 (en) | 2002-08-08 | 2004-02-25 | Dharmacon, Inc. | Short interfering rnas having a hairpin structure containing a non-nucleotide loop |
| GB0321805D0 (en) | 2003-09-18 | 2003-10-15 | Univ Wales Medicine | Human tumour growth patterns |
| EP1526177A1 (en) | 2003-10-24 | 2005-04-27 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
| WO2005111238A2 (en) * | 2004-04-19 | 2005-11-24 | Archemix Corporation | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
| PT1768677E (pt) | 2004-07-02 | 2008-10-06 | Creabilis Therapeutics Spa | Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1 |
| JP2009508473A (ja) * | 2005-08-26 | 2009-03-05 | アーケミツクス・コーポレイシヨン | 高親和性でトロンビンに結合するアプタマー |
| WO2008054431A2 (en) | 2005-12-23 | 2008-05-08 | Board Of Regents Of The University Of Texas System | Anti-hyperproliferative therapies targeting hdgf |
| PL2135949T3 (pl) * | 2006-02-14 | 2013-03-29 | Noxxon Pharma Ag | Kwasy nukleinowe wiążące MCP-1 |
| US8367629B2 (en) * | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| JP5380287B2 (ja) * | 2006-07-18 | 2014-01-08 | ノクソン・ファルマ・アクチエンゲゼルシャフト | Ｓｄｆ−１結合核酸 |
-
2009
- 2009-06-10 WO PCT/EP2009/004186 patent/WO2009149921A2/en not_active Ceased
- 2009-06-10 EP EP09761484A patent/EP2304031A2/en not_active Withdrawn
- 2009-06-10 CA CA2727285A patent/CA2727285A1/en not_active Abandoned
- 2009-06-10 JP JP2011512892A patent/JP5559159B2/ja not_active Expired - Fee Related
- 2009-06-10 US US12/997,720 patent/US8710021B2/en not_active Expired - Fee Related
- 2009-06-10 AU AU2009256906A patent/AU2009256906A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ni et al. | Chemical modifications of nucleic acid aptamers for therapeutic purposes | |
| TWI784934B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| ES2857702T3 (es) | Oligonucleótidos para la reducción de la expresión de PD-L1 | |
| US8440637B2 (en) | Combination treatment for the treatment of hepatitis C virus infection | |
| JP2014527401A5 (enExample) | ||
| US20180179521A1 (en) | Modified crispr rna and modified single crispr rna and uses thereof | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| US9725715B2 (en) | Signal activatable constructs and related components compositions methods and systems | |
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| JP2010524486A (ja) | β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 | |
| JP5559159B2 (ja) | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 | |
| Varizhuk et al. | G4 aptamers: trends in structural design | |
| TW202408542A (zh) | 製備環狀ｒｎａ的方法 | |
| Romanucci et al. | Hairpin oligonucleotides forming G-quadruplexes: New aptamers with anti-HIV activity | |
| CN119604311A (zh) | FN3结构域-siRNA缀合物与酶替代疗法 | |
| US20230340496A1 (en) | Aptamer template and method for preparing aptamer by using same | |
| JP2025039668A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| US20150353933A1 (en) | Aptamer against midkine and applications thereof | |
| Shearer et al. | The clinical potential of l-oligonucleotides: challenges and opportunities | |
| CN118984717A (zh) | Arnatar化合物和用于增强细胞摄取的方法 | |
| WO2021122735A1 (en) | Use of sept9 inhibitors for treating hepatitis b virus infection | |
| CN113728102A (zh) | 使用剪接调节化合物进行新抗原工程化 | |
| CN111212909A (zh) | 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物 | |
| JP2023506540A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 | |
| EP3124611B1 (en) | Aptamer for fgf2 and use thereof |